GLP-1 Analogues Market Outlook: Rapid Growth at 21.3% CAGR to Surpass USD 322.85 Billion by 2034 | PMR
The ability to act upon more than one disease and disorder has led to the GLP-1 analogues market has been getting a ...
News Medical on MSN9d
Exenatide, a GLP-1 analog, by IV during cardiac surgery did not reduce organ injury or death
A large-scale clinical trial found that intravenous infusion of exenatide, a glucagon-like peptide-1 (GLP-1) analog ...
Yahoo Finance8d
GLP-1 Analogues Market Outlook: Rapid Growth at 21.3% CAGR to Surpass USD 322.85 Billion by 2034 | PMR
New York, USA, Nov. 19, 2024 (GLOBE NEWSWIRE) -- Market Overview: The global GLP-1 analogues market size was assessed at USD 46.70 billion in 2024. The market is expected to flourish and grow from ...
Mena FN8d
GLP-1 Analogues Market Outlook: Rapid Growth At 21.3% CAGR To Surpass USD 322.85 Billion By 2034 | PMR
(MENAFN- GlobeNewsWire - Nasdaq) The ability to act upon more than one disease and disorder has led to the GLP-1 analogues market has been getting a tremendous boost globally in recent times.
Yahoo Finance10d
Exenatide, a GLP-1 analog, by IV during cardiac surgery did not reduce organ injury or death
a glucagon-like peptide-1 (GLP-1) analog medication, during heart surgeries involving bypass did not significantly reduce the risk of death, stroke or organ failure. Researchers presented this ...
Medpage Today on MSN1d
Thyroid Drug & Bone Loss; GLP-1s' Renal Benefit; Menopause Musculoskeletal Syndrome
The thyroid medication levothyroxine may be associated with bone loss, according to a study that will be presented at the ...